Mesenchymal stem cell-derived extracellular vesicles for dry eye disease: principles, progress, and challenges

Abstract

Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by disruption of tear film and/or ocular surface homeostasis that represents a significant global public health concern. This review summarizes the pathogenesis of DED, with particular emphasis on the central role of ocular surface inflammation. It further comprehensively evaluates the therapeutic rationale, preclinical advances, and translational challenges associated with mesenchymal stem cell-derived extracellular vesicle (MSC-EV) therapy for DED. MSC-EVs exhibit numerous properties, including anti-inflammatory, immunomodulatory, reparative, and regenerative effects, and offer key advantages such as a cell-free nature, low immunogenicity, minimal tumorigenic risk, high stability, and suitability for topical administration. Through advanced strategies such as cargo engineering, hybrid design, biomaterial-assisted delivery, and genetic engineering, the therapeutic performance of MSC-EVs can be further optimized, enabling targeted delivery, improved retention and bioavailability, and precise immunomodulation. In addition, three-dimensional ocular surface and ex vivo models help overcome the limitations of traditional animal models in replicating human ocular physiology. Among available sources, umbilical cord-derived MSC-EVs represent one of the most promising candidates for clinical translation. Despite these advances, several challenges remain, including ocular-specific anatomical and physiological barriers, limited pharmacological characterization, lack of standardized large-scale production and storage protocols, incomplete toxicological and microbiological safety evaluation, and the absence of a unified regulatory framework. Overall, MSC-EVs represent a potentially transformative therapeutic strategy for the management of refractory DED. However, as most current evidence remains preclinical, further validation in human-relevant models and clinical studies is essential before definitive conclusions can be drawn.

Keywords

Dry eye disease / mesenchymal stem cells / extracellular vesicles / inflammation / immunomodulation / exosomes

References

[1] Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al.; + TFOS collaborator group. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025;279:387-450.

[2] Ljubica J,Krtalić I.Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion.Eur J Pharm Sci2025;209:107077

[3] Kwon J,Kang C.Overview of dry eye disease for primary care physicians.Medicina2025;61:460 PMCID:PMC11943967

[4] Mohamed HB,Fathalla D.Current trends in pharmaceutical treatment of dry eye disease: a review.Eur J Pharm Sci2022;175:106206

[5] Phinney DG.Concise review: MSC-derived exosomes for cell-free therapy.Stem Cells2017;35:851-8

[6] Song N,Shah K.Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential.Trends Pharmacol Sci2020;41:653-64 PMCID:PMC7751844

[7] Buchert JM,Diederichs S.Adipose-derived stromal cells: isolation, expansion, and differentiation.Methods Mol Biol2023;2598:75-85

[8] Li H,Zacharaki D,Scheding S.Isolation and characterization of primary bone marrow mesenchymal stromal cells.Ann N Y Acad Sci2016;1370:109-18

[9] Stefańska K,Kulus M.Dental pulp stem cells - a basic research and future application in regenerative medicine.Biomed Pharmacother2024;178:116990

[10] Margiana R,Zekiy AO.Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review.Stem Cell Res Ther2022;13:366 PMCID:PMC9330677

[11] Beeravolu N,Alamri A.Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta.J Vis Exp2017;122:55224 PMCID:PMC5564456

[12] Abbaszadeh H,Derakhshani M.Regenerative potential of Wharton’s jelly-derived mesenchymal stem cells: a new horizon of stem cell therapy.J Cell Physiol2020;235:9230-40

[13] Zare E,Azad FS.Replicative senescence in amniotic fluid-derived mesenchymal stem cells and its impact on their immunomodulatory properties.Histochem Cell Biol2025;163:34

[14] Reis M,Nicholson L,Dickinson AM.Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function.Front Immunol2018;9:2538 PMCID:PMC6237916

[15] Sikora B,Prusek A.Paracrine activity of adipose derived stem cells on limbal epithelial stem cells.Sci Rep2021;11:19956 PMCID:PMC8497478

[16] Alvites R,Sousa AC,Sousa P.Mesenchymal stem/stromal cells and their paracrine activity-immunomodulation mechanisms and how to influence the therapeutic potential.Pharmaceutics2022;14:381 PMCID:PMC8875256

[17] Zhou Y,Xiao Z.The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity.J Clin Med2019;8:1025 PMCID:PMC6678920

[18] Møller-Hansen M.Mesenchymal stem cell therapy in aqueous deficient dry eye disease.Acta Ophthalmol2023;101:3-27

[19] Harrell CR,Volarevic A,Volarevic V.Molecular mechanisms responsible for mesenchymal stem cell-dependent attenuation of tear hyperosmolarity and immune cell-driven inflammation in the eyes of patients with dry eye disease.Diseases2024;12:269 PMCID:PMC11592843

[20] Yaghoubi Y,Zamani M,Mehdizadeh A.Human umbilical cord mesenchymal stem cells derived-exosomes in diseases treatment.Life Sci2019;233:116733

[21] Zhou T,Lai P.miR-204-containing exosomes ameliorate GVHD-associated dry eye disease.Sci Adv2022;8:eabj9617 PMCID:PMC8754411

[22] Farrand KF,Stillman IÖ.Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older.Am J Ophthalmol2017;182:90-8

[23] Cai Y,Zhou J.Prevalence and incidence of dry eye disease in Asia: a systematic review and meta-analysis.Ophthalmic Res2022;65:647-58

[24] Stapleton F,Asbell P.TFOS DEWS III: digest.Am J Ophthalmol2025;279:451-553

[25] Sheppard J,Periman LM.Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.Ann Med2023;55:241-52 PMCID:PMC9809411

[26] Jones L, Craig JP, Markoulli M, et al.; TFOS Collaborator Group. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289-386.

[27] Rana HS,Clabeaux CE,Aakalu VK.Ocular surface disease in thyroid eye disease: a narrative review.Ocul Surf2022;24:67-73 PMCID:PMC9058200

[28] Huang R,Fang L,Chen J.Dry eye syndrome: comprehensive etiologies and recent clinical trials.Int Ophthalmol2022;42:3253-72 PMCID:PMC9178318

[29] Donthineni PR,Basu S.Dry eye disease in children and adolescents in India.Ocul Surf2020;18:777-82

[30] Leonardi A,Cutrupi F.Dry eye and systemic diseases.Saudi J Ophthalmol2025;39:5-13 PMCID:PMC11964355

[31] Truong S,Stapleton F.Sex hormones and the dry eye.Clin Exp Optom2014;97:324-36

[32] Stapleton F,Lau C.Dry eye disease in the young: a narrative review.Ocul Surf2024;31:11-20

[33] Narang P,D’Souza S.Evaporative dry eye disease due to meibomian gland dysfunction: preferred practice pattern guidelines for diagnosis and treatment.Indian J Ophthalmol2023;71:1348-56 PMCID:PMC10276722

[34] Rolando M.Management strategies for evaporative dry eye disease and future perspective.Curr Eye Res2022;47:813-23

[35] Ma J,Guo W.Association of different digital media experiences with paediatric dry eye in China: a population-based study.BMJ Open2022;12:e062850 PMCID:PMC9717351

[36] Wang MTM,Vidal-Rohr M.Impact of digital screen use and lifestyle factors on dry eye disease in the paediatric population.Ocul Surf2022;24:64-6

[37] Tovar AA,Galor A.Living with dry eye disease and its effects on quality of life: patient, optometrist, and ophthalmologist perspectives.Ophthalmol Ther2023;12:2219-26 PMCID:PMC10441920

[38] Santos G,Silva B,Gonçalves L.Topical ocular drug delivery: the impact of permeation enhancers.Pharmaceutics2025;17:447 PMCID:PMC12030643

[39] Willcox MDP,Georgiev GA.TFOS DEWS II tear film report.Ocul Surf2017;15:366-403 PMCID:PMC6035753

[40] Winiarczyk M,Michalak K,Mackiewicz J.Changes in tear proteomic profile in ocular diseases.Int J Environ Res Public Health2022;19:13341 PMCID:PMC9603516

[41] Liu H,Chen M.A link between tear instability and hyperosmolarity in dry eye.Invest Ophthalmol Vis Sci2009;50:3671-9

[42] Guindolet D,Gabison EE.Alleviation of endoplasmic reticulum stress enhances human corneal epithelial cell viability under hyperosmotic conditions.Int J Mol Sci2022;23:4528 PMCID:PMC9104051

[43] Craig JP,Azar DT.TFOS DEWS II report executive summary.Ocul Surf2017;15:802-12

[44] Bron AJ.Tear osmolarity in the diagnosis of systemic dehydration and dry eye disease.Diagnostics2021;11:387 PMCID:PMC7996182

[45] Harrell CR.Ion channels as potential drug targets in dry eye disease and their clinical relevance: a review.Cells2024;13:2017 PMCID:PMC11639998

[46] Guzmán M,Keitelman I.Transient tear hyperosmolarity disrupts the neuroimmune homeostasis of the ocular surface and facilitates dry eye onset.Immunology2020;161:148-61 PMCID:PMC7496787

[47] Zhuang D,Mugisho OO,Craig JP.NLRP3 inflammasome as a potential therapeutic target in dry eye disease.Int J Mol Sci2023;24:10866 PMCID:PMC10341612

[48] Gou Q,Gong Y.TRPV1 in dry eye disease.Front Biosci2024;29:175

[49] Pan Z,Yang H,Reinach PS.TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells.Invest Ophthalmol Vis Sci2011;52:485-93 PMCID:PMC3053292

[50] Luo L,Pflugfelder SC.Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways.Cornea2007;26:452-60

[51] Pflugfelder SC.The cornea in keratoconjunctivitis sicca.Exp Eye Res2020;201:108295 PMCID:PMC7736263

[52] Wang HH,Huang YH.Interleukin-20 is involved in dry eye disease and is a potential therapeutic target.J Biomed Sci2022;29:36 PMCID:PMC9178884

[53] Kumar R,Khan SH.NFAT5, which protects against hypertonicity, is activated by that stress via structuring of its intrinsically disordered domain.Proc Natl Acad Sci U S A2020;117:20292-7 PMCID:PMC7443939

[54] Dai Y,Xiang J,Wu D.Calcitriol inhibits ROS-NLRP3-IL-1β signaling axis via activation of Nrf2-antioxidant signaling in hyperosmotic stress stimulated human corneal epithelial cells.Redox Biol2019;21:101093 PMCID:PMC6313824

[55] Zhang J,Yang Y.Calcitriol alleviates hyperosmotic stress-induced corneal epithelial cell damage via inhibiting the NLRP3-ASC-Caspase-1-GSDMD pyroptosis pathway in dry eye disease.J Inflamm Res2021;14:2955-62 PMCID:PMC8274828

[56] Chen H,Li Y.NLRP12- and NLRC4-mediated corneal epithelial pyroptosis is driven by GSDMD cleavage accompanied by IL-33 processing in dry eye.Ocul Surf2020;18:783-94

[57] Yang X,Zeng H.IFN-γ facilitates corneal epithelial cell pyroptosis through the JAK2/STAT1 pathway in dry eye.Invest Ophthalmol Vis Sci2023;64:34 PMCID:PMC10064915

[58] Han Y,Yuan K,Jin X.Hyperosmolarity promotes macrophage pyroptosis by driving the glycolytic reprogramming of corneal epithelial cells in dry eye disease.Front Med2023;17:781-95

[59] Deng K,Liang J.Peptide DFCPPGFNTK mitigates dry eye pathophysiology by suppressing oxidative stress, apoptosis, inflammation, and autophagy: evidence from in vitro and in vivo models.Curr Issues Mol Biol2025;47:441 PMCID:PMC12191653

[60] Bu J,Zhang R.Potential new target for dry eye disease-oxidative stress.Antioxidants2024;13:422 PMCID:PMC11047456

[61] Jiang E,Liu J.Comparison of the therapeutic effects of rebamipide and diquafosol on apoptotic damage of the ocular surface in dry eyes.Antioxidants2025;14:780 PMCID:PMC12291863

[62] Hu R,Xie CM.Dry eye disease: oxidative stress on ocular surface and cutting-edge antioxidants.Glob Chall2025;9:e00068 PMCID:PMC12246734

[63] Craig JP,Akpek EK.TFOS DEWS II definition and classification report.Ocul Surf2017;15:276-83

[64] Ashok N,D’Souza S.Ion channels in dry eye disease.Indian J Ophthalmol2023;71:1215-26 PMCID:PMC10276728

[65] Kang MJ,Kim MS.The correlation between matrix metalloproteinase-9 point-of-care immunoassay, tear film osmolarity, and ocular surface parameters.J Ophthalmol2022;2022:6132016 PMCID:PMC9017586

[66] Choi M,Ko BY.Comparative evaluation of matrix metalloproteinase-9 immunoassay and tear osmolarity measurement for diagnosing severity of dry eye disease.Korean J Ophthalmol2023;37:409-16 PMCID:PMC10587457

[67] Jamerson EC,ElSheikh RH,El Sayed YM.Role of matrix metalloproteinase 9 in ocular surface disorders.Eye Contact Lens2020;46:S57-63

[68] Harrell CR,Djonov V,Volarevic V.The molecular mechanisms responsible for tear hyperosmolarity-induced pathological changes in the eyes of dry eye disease patients.Cells2023;12:2755 PMCID:PMC10706334

[69] Li DQ,Chen Z,Song XJ.JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells.Exp Eye Res2006;82:588-96 PMCID:PMC2198933

[70] Sabio G.TNF and MAP kinase signalling pathways.Semin Immunol2014;26:237-45 PMCID:PMC4099309

[71] Luo L,Doshi A,Corrales RM.Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface.Invest Ophthalmol Vis Sci2004;45:4293-301

[72] Perez VL,Pflugfelder SC.Inflammatory basis for dry eye disease flares.Exp Eye Res2020;201:108294 PMCID:PMC7736538

[73] Zhao D,Zhao H,He A.BMSC-derived exosomes regulate the Treg/Th17 balance through the miR-21-5p/TLR4/MyD88/NF-κB pathway to alleviate dry eye symptoms in mice.In Vitro Cell Dev Biol Anim2024;60:644-56

[74] Reins RY,Courson J,Redfern RL.MyD88 deficiency protects against dry eye-induced damage.Invest Ophthalmol Vis Sci2018;59:2967-76 PMCID:PMC5991808

[75] Zheng Q,Reinach PS.Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients.Exp Eye Res2015;134:133-40

[76] Ren Y,Lin Y.MiR-223 inhibits hyperosmolarity-induced inflammation through downregulating NLRP3 activation in human corneal epithelial cells and dry eye patients.Exp Eye Res2022;220:109096

[77] Chi W,Chen X.Mitochondrial DNA oxidation induces imbalanced activity of NLRP3/NLRP6 inflammasomes by activation of caspase-8 and BRCC36 in dry eye.J Autoimmun2017;80:65-76 PMCID:PMC5536896

[78] Yin X,Eisenbarth SC.Dendritic cell regulation of T helper cells.Annu Rev Immunol2021;39:759-90

[79] Reyes JL,Eksteen B.Innate and adaptive cell populations driving inflammation in dry eye disease.Mediators Inflamm2018;2018:2532314 PMCID:PMC6109495

[80] Pflugfelder SC,de Paiva CS.T helper cytokines in dry eye disease.Exp Eye Res2013;117:118-25 PMCID:PMC3855838

[81] Barabino S,Chauhan S.Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.Prog Retin Eye Res2012;31:271-85 PMCID:PMC3334398

[82] Zimmer N,Graefen B,Tuettenberg A.GARP as a therapeutic target for the modulation of regulatory T cells in cancer and autoimmunity.Front Immunol2022;13:928450 PMCID:PMC9309211

[83] Jung YH,Yoon CH.Age-dependent distinct distributions of dendritic cells in autoimmune dry eye murine model.Cells2021;10:1857 PMCID:PMC8392312

[84] Liu Z,Li L.Single-cell landscape reveals the epithelial cell-centric pro-inflammatory immune microenvironment in dry eye development.Mucosal Immunol2024;17:491-507

[85] Schaumburg CS,De Paiva CS.Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis.J Immunol2011;187:3653-62

[86] De Paiva CS,Pangelinan SB.IL-17 disrupts corneal barrier following desiccating stress.Mucosal Immunol2009;2:243-53 PMCID:PMC3594767

[87] Stern ME,Dana R,Niederkorn JY.Autoimmunity at the ocular surface: pathogenesis and regulation.Mucosal Immunol2010;3:425-42 PMCID:PMC3577924

[88] Pham TL.Docosanoid signaling modulates corneal nerve regeneration: effect on tear secretion, wound healing, and neuropathic pain.J Lipid Res2021;62:100033 PMCID:PMC7933495

[89] Fakih D,Nicolle P.Chronic dry eye induced corneal hypersensitivity, neuroinflammatory responses, and synaptic plasticity in the mouse trigeminal brainstem.J Neuroinflammation2019;16:268 PMCID:PMC6918709

[90] Sebbag L,Leland A,Kim S.Altered corneal innervation and ocular surface homeostasis in FHV-1-exposed cats: a preliminary study suggesting metaherpetic disease.Front Vet Sci2020;7:580414 PMCID:PMC7870478

[91] Belmonte C,Cox SM.TFOS DEWS II pain and sensation report.Ocul Surf2017;15:404-37 PMCID:PMC5706540

[92] Tepelus TC,Huang J.Correlation between corneal innervation and inflammation evaluated with confocal microscopy and symptomatology in patients with dry eye syndromes: a preliminary study.Graefes Arch Clin Exp Ophthalmol2017;255:1771-8

[93] Xu J,Yu C,Hu S.In vivo confocal microscopic evaluation of corneal dendritic cell density and subbasal nerve parameters in dry eye patients: a systematic review and meta-analysis.Front Med2021;8:578233 PMCID:PMC8058423

[94] Cox SM,Aggarwal S.Alterations in corneal nerves in different subtypes of dry eye disease: an in vivo confocal microscopy study.Ocul Surf2021;22:135-42 PMCID:PMC11549962

[95] Jamali A,Chao C.Intravital multiphoton microscopy of the ocular surface: alterations in conventional dendritic cell morphology and kinetics in dry eye disease.Front Immunol2020;11:742 PMCID:PMC7227427

[96] Møller-Hansen M,Toft PB.Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease.Ocul Surf2021;19:43-52

[97] Betz J.Navigating the dry eye therapeutic puzzle: a mechanism-based overview of current treatments.Pharmaceuticals2025;18:994 PMCID:PMC12298963

[98] Tong L,Şahin A.Topical pharmacologic treatments for dry eye disease: a systematic review.Ocul Surf2025;38:302-17

[99] Harrell CR,Djonov V,Volarevic V.Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases.Cells2019;8:1605 PMCID:PMC6952783

[100] Shen Z,Liu J,Wang S.Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases.Front Immunol2021;12:749192 PMCID:PMC8503317

[101] Li N,Wei Y,Nian H.Recent advances of exosomes in immune-mediated eye diseases.Stem Cell Res Ther2019;10:278 PMCID:PMC6716826

[102] Bhujel B,Kim CM.Mesenchymal stem cells and exosomes: a novel therapeutic approach for corneal diseases.Int J Mol Sci2023;24:10917 PMCID:PMC10341647

[103] Pitt JM,Zitvogel L.Extracellular vesicles: masters of intercellular communication and potential clinical interventions.J Clin Invest2016;126:1139-43 PMCID:PMC4811136

[104] Colombo M,Théry C.Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.Annu Rev Cell Dev Biol2014;30:255-89

[105] Li SJ,Wei SX,Pu YY.Advances in mesenchymal stem cell-derived extracellular vesicles therapy for Sjogren’s syndrome-related dry eye disease.Exp Eye Res2023;237:109716

[106] Kim H,Bae EH.Comprehensive molecular profiles of functionally effective MSC-derived extracellular vesicles in immunomodulation.Mol Ther2020;28:1628-44 PMCID:PMC7335740

[107] Harrell CR,Jovicic N,Arsenijevic N.Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome.Cells2019;8:467 PMCID:PMC6562906

[108] Sun SJ,Li F,Tse HF.Mesenchymal stromal cell-derived exosomes in cardiac regeneration and repair.Stem Cell Reports2021;16:1662-73 PMCID:PMC8282428

[109] Morandi MI,Ozer-Partuk E.Extracellular vesicle fusion visualized by cryo-electron microscopy.PNAS Nexus2022;1:pgac156 PMCID:PMC9802263

[110] Mathew B,Liu X.Mesenchymal stem cell-derived extracellular vesicles and retinal ischemia-reperfusion.Biomaterials2019;197:146-60 PMCID:PMC6425741

[111] van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[112] Fu X,Halim A,Luo Q.Mesenchymal stem cell migration and tissue repair.Cells2019;8:784 PMCID:PMC6721499

[113] Jiang W.Immune modulation by mesenchymal stem cells.Cell Prolif2020;53:e12712 PMCID:PMC6985662

[114] Louie HH,Chamley LW.Extracellular vesicles as biomarkers and therapeutics for inflammatory eye diseases.Mol Pharm2023;20:23-40

[115] Kolenc A.Current methods for analysing mesenchymal stem cell-derived extracellular vesicles.Int J Mol Sci2024;25:3439 PMCID:PMC10970230

[116] Holcar M,Lenassi M.Blood nanoparticles - influence on extracellular vesicle isolation and characterization.Front Pharmacol2021;12:773844 PMCID:PMC8635996

[117] Murphy DE,Brouwer M.Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking.Exp Mol Med2019;51:1-12 PMCID:PMC6418170

[118] Toh WS,Zhang B.MSC exosome works through a protein-based mechanism of action.Biochem Soc Trans2018;46:843-53 PMCID:PMC6103455

[119] Bhujel B,Choi DJ.Mesenchymal stem cell-derived exosomes and intervertebral disc regeneration: review.Int J Mol Sci2022;23:7306 PMCID:PMC9267028

[120] Hefley BS,Vasini B.Revealing the presence of tear extracellular vesicles in Keratoconus.Exp Eye Res2022;224:109242 PMCID:PMC10159047

[121] Amin S,Katz E.The limbal niche and regenerative strategies.Vision2021;5:43 PMCID:PMC8544688

[122] Jalilian E,Bigit B.Bone marrow mesenchymal stromal cells in a 3D system produce higher concentration of extracellular vesicles (EVs) with increased complexity and enhanced neuronal growth properties.Stem Cell Res Ther2022;13:425 PMCID:PMC9389821

[123] Rassi DM,Dias LC.Review: microRNAS in ocular surface and dry eye diseases.Ocul Surf2017;15:660-9

[124] Munir J,Ryu S.Therapeutic miRNA-enriched extracellular vesicles: current approaches and future prospects.Cells2020;9:2271 PMCID:PMC7601381

[125] Qian X,Ren Y,Zhang X.Immunosuppressive effects of mesenchymal stem cells-derived exosomes.Stem Cell Rev Rep2021;17:411-27

[126] Xu HK,Zhou SN,Xiang C.Multifunctional role of microRNAs in mesenchymal stem cell-derived exosomes in treatment of diseases.World J Stem Cells2020;12:1276-94 PMCID:PMC7705472

[127] Wang L,Chen Q.MicroRNAs of extracellular vesicles derived from mesenchymal stromal cells alleviate inflammation in dry eye disease by targeting the IRAK1/TAB2/NF-κB pathway.Ocul Surf2023;28:131-40

[128] Habibi A,Soleimani M,Dara M.Efficacy of topical mesenchymal stem cell exosome in Sjögren’s syndrome-related dry eye: a randomized clinical trial.BMC Ophthalmol2025;25:299 PMCID:PMC12090426

[129] Chan SM,Lee TP,Huang WH.Therapeutic potential of umbilical cord MSC-derived exosomes in a severe dry eye rat model: enhancing corneal protection and modulating inflammation.Biomedicines2025;13:1174 PMCID:PMC12108626

[130] Wang G,Liu Y,Zeng L.Mesenchymal stem cells-derived exosomal miR-223-3p alleviates ocular surface damage and inflammation by downregulating Fbxw7 in dry eye models.Invest Ophthalmol Vis Sci2024;65:1 PMCID:PMC11451833

[131] Yu C,Xu J.hADSCs derived extracellular vesicles inhibit NLRP3inflammasome activation and dry eye.Sci Rep2020;10:14521 PMCID:PMC7471690

[132] Wang G,Long H,Hu S.Exosomes derived from mouse adipose-derived mesenchymal stem cells alleviate benzalkonium chloride-induced mouse dry eye model via inhibiting NLRP3 inflammasome.Ophthalmic Res2022;65:40-51

[133] Chopra P,Mohapatra S.Extracellular vesicles in dry eye disease and Sjögren’s syndrome: a systematic review on their diagnostic and therapeutic role.Surv Ophthalmol2025;70:499-515 PMCID:PMC7617721

[134] Guo R,He Y.Mesenchymal stromal cells-derived extracellular vesicles regulate dendritic cell functions in dry eye disease.Cells2022;12:33 PMCID:PMC9818747

[135] Li N,Zhao L.MSC-derived small extracellular vesicles attenuate autoimmune dacryoadenitis by promoting M2 macrophage polarization and inducing Tregs via miR-100-5p.Front Immunol2022;13:888949 PMCID:PMC9298967

[136] Yan L,Cai X.Macrophage plasticity: signaling pathways, tissue repair, and regeneration.MedComm2024;5:e658 PMCID:PMC11292402

[137] Ren Y,An N.Periodontal ligament stem cell-derived exosomes regulate Muc5ac expression in rat conjunctival goblet cells via regulating macrophages toward an anti-inflammatory phenotype.Ocul Immunol Inflamm2024;32:1990-9

[138] Bjordal O,Rødahl E,Omdal R.Primary Sjögren’s syndrome and the eye.Surv Ophthalmol2020;65:119-32

[139] Li B,Gan Y,Hua H.Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sjögren’s syndrome by modulating the balance of Treg and Th17 cells.Stem Cell Res Ther2021;12:478 PMCID:PMC8390194

[140] Ma D,Zhao X.Immunomodulatory effects of umbilical mesenchymal stem cell-derived exosomes on CD4⁺ T cells in patients with primary Sjögren’s syndrome.Inflammopharmacology2023;31:1823-38 PMCID:PMC10352432

[141] Xing Y,He J.Labial gland mesenchymal stem cell derived exosomes-mediated miRNA-125b attenuates experimental Sjogren’s syndrome by targeting PRDM1 and suppressing plasma cells.Front Immunol2022;13:871096 PMCID:PMC9014006

[142] Shen T,Shen J.Effects of adipose-derived mesenchymal stem cell exosomes on corneal stromal fibroblast viability and extracellular matrix synthesis.Chin Med J2018;131:704-12 PMCID:PMC5865317

[143] Dogru M,Yamamoto Y.Lactoferrin in Sjögren’s syndrome.Ophthalmology2007;114:2366-7

[144] Foulsham W,Mittal SK.Thrombospondin-1 in ocular surface health and disease.Ocul Surf2019;17:374-83 PMCID:PMC6708501

[145] Liu X,Wu G.Umbilical cord mesenchymal stem cell-derived small extracellular vesicles deliver miR-21 to promote corneal epithelial wound healing through PTEN/PI3K/Akt pathway.Stem Cells Int2022;2022:1252557 PMCID:PMC9303509

[146] Tati V,Basu S.Bone marrow mesenchymal stem cell-derived extracellular vesicles promote corneal epithelial repair and suppress apoptosis via modulation of Caspase-3 in vitro.FEBS Open Bio2024;14:968-82 PMCID:PMC11494918

[147] Tati V,Shukla S.Mesenchymal vs. epithelial extracellular vesicles in corneal epithelial repair, apoptosis, and immunomodulation: an in vitro study.Exp Eye Res2024;247:110027

[148] Ryu Y,Bo Noh K,Seo JH.Adipose mesenchymal stem cell-derived exosomes promote the regeneration of corneal endothelium through ameliorating senescence.Invest Ophthalmol Vis Sci2023;64:29 PMCID:PMC10593138

[149] Liu Q,Pan X.Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification.J Nanobiotechnology2023;21:334 PMCID:PMC10505332

[150] Xu H,Zhou H.Engineered small extracellular vesicles as bioactive materials: integrating engineering strategies for cargo loading and targeted delivery systems.Bioact Mater2026;59:96-134 PMCID:PMC13045864

[151] Khristov V,Caton-Darby M,Sundstrom JM.Diagnostic and therapeutic utility of extracellular vesicles in ocular disease.Int J Mol Sci2025;26:836 PMCID:PMC11765869

[152] Salunkhe S,Basak M,Mittal A.Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance.J Control Release2020;326:599-614

[153] Flores C,Huang L.Extracellular vesicles in ophthalmology: from natural nanocarriers to engineered therapeutics.Bioengineering2026;13:275 PMCID:PMC13024458

[154] Tian Y,Zhao J.Combining MSC exosomes and cerium oxide nanocrystals for enhanced dry eye syndrome therapy.Pharmaceutics2023;15:2301 PMCID:PMC10536361

[155] Ma F,Liu X.A synergistic therapeutic nano-eyedrop for dry eye disease based on ascorbic acid-coupled exosomes.Nanoscale2023;15:1890-9

[156] Kang M,Tsai B,Blenkiron C.Placental extracellular vesicles can be loaded with plasmid DNA.Mol Pharm2023;20:1898-913 PMCID:PMC11407900

[157] Wu P,Ocansey DKW,Qian H.Extracellular vesicles: a bright star of nanomedicine.Biomaterials2021;269:120467

[158] Xie M,Zhang Y.Membrane fusion-mediated loading of therapeutic siRNA into exosome for tissue-specific application.Adv Mater2024;36:e2403935

[159] Tang Q,He J.Exosomes-loaded thermosensitive hydrogels for corneal epithelium and stroma regeneration.Biomaterials2022;280:121320

[160] Sun X,Teng L.MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing.Bioact Mater2023;25:640-56 PMCID:PMC10086767

[161] Giri BR,Sandoval MA,Bao Q.Advancements in ocular therapy: a review of emerging drug delivery approaches and pharmaceutical technologies.Pharmaceutics2024;16:1325 PMCID:PMC11511072

[162] Bairagi RD,Hasan MM.Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discov Nano2025;20:75 PMCID:PMC12049359

[163] Lee J,Nguyen VP,Paulus YM.Microneedles for controlled and sustained intraocular drug delivery.NPG Asia Mater2025;17:33 PMCID:PMC12370535

[164] Gratieri T,Rocha EM,de Freitas O.A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery.Eur J Pharm Biopharm2010;75:186-93

[165] Xie Y,Xing Y,Wei P.miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjögren’s syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis.J Nanobiotechnology2025;23:228 PMCID:PMC11927278

[166] Gaudana R,Parenky A.Ocular drug delivery.AAPS J2010;12:348-60 PMCID:PMC2895432

[167] Prina E,Sidney LE.3D microfabricated scaffolds and microfluidic devices for ocular surface replacement: a review.Stem Cell Rev Rep2017;13:430-41

[168] Bennet D,Reid T.A microengineered human corneal epithelium-on-a-chip for eye drops mass transport evaluation.Lab Chip2018;18:1539-51

[169] Kim M,Lin A.Current and future cornea chip models for advancing ophthalmic research and therapeutics.Adv Biol2025;9:e2400571 PMCID:PMC12264468

[170] Wan X,Zhou X.Establishment of human corneal epithelial organoids for ex vivo modelling dry eye disease.Cell Prolif2024;57:e13704 PMCID:PMC11533071

[171] Jeong SY,Jeon SG.Establishment of functional epithelial organoids from human lacrimal glands.Stem Cell Res Ther2021;12:247 PMCID:PMC8059179

[172] Hayashi R,Kudo Y.Generation of 3D lacrimal gland organoids from human pluripotent stem cells.Nature2022;605:126-31

[173] Bannier-Hélaouët M,Korving J.Exploring the human lacrimal gland using organoids and single-cell sequencing.Cell Stem Cell2021;28:1221-32.e7

[174] Yu C,Wei J.Human meibomian gland organoids to study epithelial homeostasis and dysfunction.Protein Cell2025;Epub ahead of print:

[175] Seo J,Alisafaei F.Multiscale reverse engineering of the human ocular surface.Nat Med2019;25:1310-8 PMCID:PMC6950645

[176] Wang Y,Yang M.Construction of dome-shaped 3D corneal epithelial tissue models based on eyeball-shaped gel microspheres.ACS Appl Mater Interfaces2024;16:31597-609

[177] Ferreira JN,Chaisuparat R.Unveiling senescence-associated ocular pathogenesis via lacrimal gland organoid magnetic bioassembly platform and HMGB1-Box A gene therapy.Sci Rep2024;14:21784 PMCID:PMC11410968

[178] Ma SC,Wang Q,Wu HZ.Application of eye organoids in the study of eye diseases.Exp Eye Res2024;247:110068

[179] Abdal Dayem A,Lim N.Advances in lacrimal gland organoid development: techniques and therapeutic applications.Biomed Pharmacother2025;183:117870

[180] Dunn CM,Grainger DW.Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies.Acta Biomater2021;133:114-25

[181] Jammes M,Bach T.Healing the cornea: exploring the therapeutic solutions offered by MSCs and MSC-derived EVs.Prog Retin Eye Res2025;105:101325

[182] Blanco NG,Castro LL.Extracellular vesicles from different sources of mesenchymal stromal cells have distinct effects on lung and distal organs in experimental sepsis.Int J Mol Sci2023;24:8234 PMCID:PMC10179270

[183] Gupta S,Soni N,Banerjee A.Comparative proteomic profiling of small extracellular vesicles derived from iPSCs and tissue specific mesenchymal stem cells.Exp Cell Res2022;420:113354

[184] Li Y,Liu BY.Deciphering the heterogeneity landscape of mesenchymal stem/stromal cell-derived extracellular vesicles for precise selection in translational medicine.Adv Healthc Mater2023;12:e2202453 PMCID:PMC11468895

[185] Dalle Carbonare L,Braggio M.Extracellular vesicles in osteogenesis: comparative analysis of stem cell sources, conditioning strategies, and in vitro models toward advanced bone regeneration.Cells2025;15:27 PMCID:PMC12786284

[186] Gorgun C,Reverberi D.Role of extracellular vesicles from adipose tissue- and bone marrow-mesenchymal stromal cells in endothelial proliferation and chondrogenesis.Stem Cells Transl Med2021;10:1680-95 PMCID:PMC8641083

[187] ISEV2025 abstract book.J Extracell Vesicles2025;14:e70157 PMCID:PMC12560119

[188] Lelek J.Perspectives for future use of extracellular vesicles from umbilical cord- and adipose tissue-derived mesenchymal stem/stromal cells in regenerative therapies-synthetic review.Int J Mol Sci2020;21:799 PMCID:PMC7036930

[189] Tseng AM,Heur M.Cell free regenerative extracellular vesicle therapy for ocular diseases.Curr Eye Res2025;50:1297-311 PMCID:PMC12710449

[190] Shimizu Y,Matsuura N.Mesenchymal stromal cell-derived extracellular vesicles in regenerative medicine: standardisation, bioengineering and clinical translation.Regen Ther2026;31:101058 PMCID:PMC12796862

[191] Fernández-Pérez AG,López-Naranjo EJ.Extracellular vesicles from different mesenchymal stem cell types exhibit distinctive surface protein profiling and molecular characteristics: a comparative analysis.Int J Mol Sci2025;26:3393 PMCID:PMC11989379

[192] He J,Wang W.Exosomal targeting and its potential clinical application.Drug Deliv Transl Res2022;12:2385-402 PMCID:PMC9458566

[193] Tian B,Doherty S.Ocular drug delivery: advancements and innovations.Pharmaceutics2022;14:1931 PMCID:PMC9506479

[194] Yang Y.Topical ocular drug delivery systems: innovations for an unmet need.Exp Eye Res2022;218:109006

[195] Grassiri B,Bernkop-Schnürch A.Strategies to prolong the residence time of drug delivery systems on ocular surface.Adv Colloid Interface Sci2021;288:102342

[196] Patel A,Agrahari V.Ocular drug delivery systems: an overview.World J Pharmacol2013;2:47-64 PMCID:PMC4289909

[197] Xu Y,Ma L.3D mesenchymal stem cell exosome-functionalized hydrogels for corneal wound healing.J Control Release2025;380:630-46

[198] Millán Cotto HA,Hakim B.Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors.J Mater Chem B2024;12:7384-400 PMCID:PMC11323772

[199] Feng K,Yuan J.Reversing the surface charge of MSC-derived small extracellular vesicles by εPL-PEG-DSPE for enhanced osteoarthritis treatment.J Extracell Vesicles2021;10:e12160 PMCID:PMC8559985

[200] Wu H,Zhang M.A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization.J Nanobiotechnology2024;22:290 PMCID:PMC11129376

[201] Foo JB,How CW.Mesenchymal stem cell-derived exosomes and microRNAs in cartilage regeneration: biogenesis, efficacy, miRNA enrichment and delivery.Pharmaceuticals2021;14:1093 PMCID:PMC8618513

[202] Wang X.Mesenchymal stem cell-derived small extracellular vesicles and bone regeneration.Basic Clin Pharmacol Toxicol2021;128:18-36 PMCID:PMC7820981

[203] Burnouf T,Agrahari V.Extracellular vesicles as nanomedicine: hopes and hurdles in clinical translation.Int J Nanomedicine2019;14:8847-59 PMCID:PMC6859699

[204] Hua S,Gulati K,Ivanovski S.Periodontal and dental pulp cell-derived small extracellular vesicles: a review of the current status.Nanomaterials2021;11:1858 PMCID:PMC8308278

[205] Tamrin SH,Nezhad AS.Critical considerations in determining the surface charge of small extracellular vesicles.J Extracell Vesicles2023;12:e12353 PMCID:PMC10457570

[206] Saftics A,Romano E.Single extracellular VEsicle nanoscopy.J Extracell Vesicles2023;12:e12346 PMCID:PMC10329735

[207] Sanghani A,Kafetzis KN,Yu-Wai-Man C.Advances in exosome therapies in ophthalmology-From bench to clinical trial.Acta Ophthalmol2022;100:243-52

[208] Wiklander OPB,Lötvall J,El Andaloussi S.Advances in therapeutic applications of extracellular vesicles.Sci Transl Med2019;11:eaav8521 PMCID:PMC7104415

[209] Pariset E,Millet A.Extracellular vesicles: isolation methods.Adv Biosyst2017;1:e1700040

[210] Yu LL,Liu JX.A comparison of traditional and novel methods for the separation of exosomes from human samples.Biomed Res Int2018;2018:3634563 PMCID:PMC6083592

[211] Yuan F,Wang Z.Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation.Drug Deliv2021;28:1501-9 PMCID:PMC8281093

[212] Yi S,Kim MJ,Kim KH.Development of human amniotic epithelial cell-derived extracellular vesicles as cell-free therapy for dry eye disease.Ocul Surf2024;34:370-80

[213] Syromiatnikova V,Gomzikova M.Methods of the large-scale production of extracellular vesicles.Int J Mol Sci2022;23:10522 PMCID:PMC9506336

[214] Trenkenschuh E,Heinrich E,Fuhrmann G.Enhancing the stabilization potential of lyophilization for extracellular vesicles.Adv Healthc Mater2022;11:e2100538 PMCID:PMC11468620

[215] Evtushenko EG,Lazarev VN,Khomyakova E.Adsorption of extracellular vesicles onto the tube walls during storage in solution.PLoS One2020;15:e0243738 PMCID:PMC7769454

[216] Melling GE,Conlon R,Carter DRF.The challenges and possibilities of extracellular vesicles as therapeutic vehicles.Eur J Pharm Biopharm2019;144:50-6

[217] Fujita M,Ikka T.The urgent need for clear and concise regulations on exosome-based interventions.Stem Cell Reports2024;19:1517-9 PMCID:PMC11589178